New approach to Alzheimer’s 

Scientific research increasingly suggests that addressing certain modifiable health risks such as poor diet, lack of exercise, stress, hearing or vision loss, diabetes, obesity, high cholesterol, and high blood pressure may reduce the risk of developing Alzheimer’s or slow cognitive decline. This idea offers hope to families facing a disease that currently has few effective treatments. Several studies support the potential benefits of lifestyle interventions. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) followed more than 1,200 adults aged 60–77. Participants who received guidance on diet, exercise, and cognitive training showed significant improvements in executive function, processing speed, and complex memory compared with those who did not. Another study, the Systematic Multi-Domain Alzheimer Risk Reduction Trial (SMARRT), tested personalized interventions targeting risk factors such as inactivity, hypertension, and social isolation. Participants who received individualized treatment showed a 74% greater improvement in cognitive performance compared with those in the control group. Despite these promising results, researchers caution against overstating the effectiveness of lifestyle changes. Most studies have focused on people with mild cognitive impairment rather than those already suffering from advanced dementia. Evidence that diet, supplements, or exercise can reverse Alzheimer’s or substantially improve cognition in patients with the disease remains weak. Scientists also face difficulties studying lifestyle interventions because they are harder to measure than medications-factors like exercise intensity, diet adherence, and long-term behavioral changes vary widely among individuals. At the same time, many companies market expensive programs and supplements claiming to cure or reverse Alzheimer’s, often without rigorous scientific evidence. Some treatments rely on small studies, animal research, or poorly reviewed publications, yet they form a global industry worth billions of dollars. Experts warn that these claims can financially and emotionally harm families desperate for solutions. Researchers estimate that addressing lifestyle risk factors could potentially reduce global dementia cases by about 45%, but this does not guarantee protection for individuals. Genetics, aging, and chance remain major determinants of risk.

Return to top

New "super antibiotic" stops deadly gut infection without destroying the microbiome

Scientists at Leiden University have developed an experimental antibiotic called EVG7 that may offer a more effective treatment for infections caused by Clostridioides difficile. The findings suggest that the drug can eliminate the infection using a very small dose while significantly lowering the risk of relapse-a common issue with existing treatments. C. difficile infections often occur in older adults or people with weakened health and can cause severe diarrhea and intestinal inflammation through toxin release. The new drug EVG7 is designed as a stronger and more efficient version of Vancomycin, one of the standard antibiotics used to treat C. difficile infections. In experiments led by researcher Elma Mons, scientists tested EVG7 in mice infected with C. difficile. Because the drug is significantly more potent than vancomycin, researchers evaluated it at a much smaller dose. The team investigated why the smaller dose worked best by examining the mice’s gut microbiome, the community of bacteria living in the intestines. They discovered that low-dose EVG7 preserved many beneficial microbes, particularly bacteria from the Lachnospiraceae. These microbes help suppress C. difficile by preventing its spores from developing into harmful bacteria. This contrasts with many conventional antibiotics, which often destroy large portions of the gut microbiome-including protective bacteria-making it easier for C. difficile to return. By sparing helpful microbes, EVG7 aligns with a growing medical approach focused on preserving the microbiome during treatment. Early results suggest that even at a low dose, EVG7 effectively kills C. difficile and may reduce the likelihood of resistance developing. Although the findings are promising, the research has so far been conducted only in mice. Further studies and human clinical trials will be needed to confirm whether EVG7 can safely and effectively treat C. difficile infections in people.

Return to top

A pill for sleep apnea 

A medication called Sulthiame may provide a promising new treatment for Obstructive Sleep Apnea, according to a European clinical trial involving researchers from the University of Gothenburg. The findings suggest the drug could significantly reduce night time breathing interruptions and improve oxygen levels in people with moderate to severe sleep apnea. The study enrolled 298 participants across four European countries and used a double-blind clinical trial design, meaning neither participants nor researchers knew who received the active drug or a placebo during the experiment. One quarter of the participants were given a placebo, while the rest received varying doses of sulthiame. Researchers then measured changes in breathing interruptions during sleep and overall oxygen levels. The results showed a substantial improvement among patients receiving higher doses of sulthiame. These individuals experienced up to 47% fewer breathing pauses during sleep compared with those in the placebo group. They also demonstrated better oxygen saturation overnight, indicating more stable breathing patterns during sleep. Most side effects reported during the study were mild and temporary, suggesting the treatment was generally well tolerated. Scientists believe sulthiame works by stabilizing the brain’s control of breathing and increasing respiratory drive. This mechanism helps prevent the collapse of the upper airway during sleep, which is the main cause of obstructive sleep apnea. The research was led in part by Jan Hedner from the Sahlgrenska Academy, with contributions from Ludger Grote and Kaj Stenlöf. Hedner described the findings as a potential breakthrough, emphasizing that they show sleep apnea may be treatable through medication rather than relying solely on mechanical devices. Currently, the most common treatment for sleep apnea is continuous positive airway pressure (CPAP) therapy, which keeps the airway open using a breathing mask. Although effective, many patients struggle to tolerate CPAP, and up to half stop using it within a year due to discomfort or disrupted sleep. Sulthiame has previously been approved to treat certain forms of childhood epilepsy, but researchers are now exploring its potential role in sleep medicine. While the trial results are encouraging, scientists stress that larger and longer-term studies are needed to confirm whether the drug remains effective and safe for broader patient population.

Return to top

New pancreatic cancer treatments

Researchers from Massachusetts Institute of Technology and Dana-Farber Cancer Institute have identified a new potential target for treating Pancreatic Cancer, one of the deadliest cancers. Their findings suggest that previously overlooked molecules called cryptic peptides could help guide new immunotherapy strategies. Pancreatic cancer is extremely difficult to treat, with only about 10% of patients surviving five years after diagnosis. Current treatments typically involve surgery, chemotherapy, and radiation. However, many modern immunotherapies—such as checkpoint inhibitors—have shown limited effectiveness against pancreatic tumors. Because of this, scientists are searching for new targets that could enable the immune system to recognize and attack these cancer cells. In this study, researchers focused on cryptic peptides, which are small protein fragments produced from parts of the genome that were previously thought not to code for proteins. While some cryptic peptides appear in normal tissues, the team discovered around 1,700 such peptides in pancreatic tumor samples, with roughly 500 appearing only in cancer cells and not in healthy tissues. These tumor-specific peptides could serve as promising targets for immune-based treatments. To identify them, scientists used a technique called immunopeptidomics, which isolates peptides displayed on cell surfaces and identifies them using mass spectrometry. Tumor samples from about a dozen patients were used to create organoids—three-dimensional mini-tumor models that replicate aspects of pancreatic tissue. Analysis showed that cryptic peptides represented the largest group of new antigens present on these tumor cells. The researchers then tested whether the immune system could target these molecules. They exposed several of the cancer-specific peptides to immature T cells and found that 12 peptides triggered strong T-cell responses. The team engineered T cells to recognize these antigens and tested them against patient-derived tumor organoids. The modified immune cells successfully destroyed pancreatic tumor organoids in laboratory experiments. According to Tyler Jacks, the findings reveal an unexpected vulnerability in pancreatic cancer cells that could be exploited for future treatments. Researchers believe these tumor-specific peptides may eventually help guide T-cell therapies or other targeted immunotherapies, offering new hope against a cancer that currently has very limited treatment options.

Return to top

Researchers say an experimental medicine originally studied for type 2 diabetes may also help protect the heart. In a new study, scientists found that a drug called IC7Fc can lower cholesterol, reduce blood fats, and slow the buildup of fatty plaques in arteries, all important factors linked to heart disease. The research was carried out by an international team led by scientists. Their findings were published in the journal Science Advances. The study tested IC7Fc in mice that are genetically prone to developing heart disease. According to the researchers, the drug significantly reduced levels of triglycerides and cholesterol in the blood. It also helped prevent fatty deposits from building up in blood vessels, a process known as atherosclerosis. This condition can narrow the arteries and increase the risk of heart attacks and strokes. Scientists also observed that IC7Fc reduced inflammation in the body. Inflammation is known to play a major role in the development of heart disease, so lowering it may help protect the cardiovascular system. Interestingly, the benefits appeared even without weight loss. In earlier studies involving obese mice, IC7Fc reduced appetite and body fat. However, in the new study involving lean mice with high cholesterol, the drug improved heart health without affecting body weight or food intake. Researchers say this suggests the drug could help people at risk of heart disease even if they are not overweight. Although these findings are promising, scientists stress that the research is still in the early stages. Further studies and human clinical trials will be needed to confirm whether IC7Fc can safely treat heart and metabolic diseases in people.

Return to top

A New Pill to Fight “Bad” Cholesterol

A new experimental pill called enlicitide may offer a powerful and convenient way to lower “bad” cholesterol and protect heart health. In a large clinical trial, researchers found that the drug reduced LDL cholesterol by about 60%—a level similar to some of the most effective injectable treatments available today. LDL cholesterol, often called “bad” cholesterol, plays a major role in heart disease. It can build up in the walls of arteries, causing them to narrow or block—a condition known as atherosclerosis. This increases the risk of heart attacks and strokes. While statins are widely used to lower cholesterol, many people still do not reach safe levels, even with treatment. The study, published in The New England Journal of Medicine, included nearly 3,000 participants. Most were already taking statins but still had higher-than-recommended cholesterol levels. After 24 weeks, those who took enlicitide experienced a significant drop in LDL cholesterol. The drug also improved other markers linked to heart disease. What makes enlicitide especially promising is that it comes in pill form. Current drugs with similar effectiveness, called PCSK9 inhibitors, are given as injections. Many patients avoid these treatments due to cost, inconvenience, or fear of needles. An oral option could make it easier for more people to get the treatment they need. Researchers say this new pill could be a major step forward in preventing heart disease. However, more studies are ongoing to confirm whether it can reduce heart attacks and strokes in the long term. If approved, enlicitide could become an important new option for managing cholesterol and improving heart health.

Return to top